视神经脊髓炎谱系疾病患者认知功能障碍的患病率及相关人口学与临床因素
该回顾性观察研究纳入219例视神经脊髓炎谱系疾病(NMOSD)患者,采用系列蒙特利尔认知评估(MoCA)评估认知功能。34%(75/219)符合认知功能障碍标准(MoCA<26),30%(45/150)系列测试显示认知下降。神经功能残疾较轻和疼痛评分较低者MoCA评分较高,高中及以上教育者MoCA评分较高,从未使用利妥昔单抗者MoCA评分高于仅使用利妥昔单抗者,黑人患者认知障碍较白人更明显。
要点
- 34%(75/219)的NMOSD患者符合认知功能障碍标准(MoCA<26)。
- 30%(45/150)的患者系列MoCA测试显示认知下降,以语言和言语回忆受损为主。
- 从未使用利妥昔单抗者MoCA评分高于仅使用利妥昔单抗者(p<0.029)。
核心结论
- 34%的NMOSD患者存在轻至中度认知功能障碍,30%的患者系列测试显示认知下降,提示需要改进和验证的筛查工具来评估NMOSD认知障碍。
研究设计与样本
- 观察性回顾性研究,具有纵向随访,描述来自NMOSD临床与纵向经验研究国际合作(Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD)的临床队列。
- 入组时及每6个月进行系列蒙特利尔认知评估(MoCA),评估纵向认知功能与人口学和疾病相关因素的关系。
- 使用双尾t检验、方差分析、χ2检验、线性回归进行单变量和校正分析,使用同时线性回归和混合效应模型进行多变量分析。
主要发现
- 34%(75/219)的患者符合认知功能障碍标准(MoCA<26);29%(64/219)为轻度功能障碍(MoCA 20-26/30),5%(11/219)为中度功能障碍(MoCA<20/30)。
- 神经功能残疾较轻和疼痛评分较低的患者MoCA评分较高(95%CI 0.24-0.65和95%CI 0.09-0.42)。
- 至少高中教育的患者MoCA评分较高(95%CI 2.2-5)。
- 按认知功能障碍二分比较时,从未使用利妥昔单抗的患者评分高于仅使用利妥昔单抗的患者(p<0.029)。
- 年化复发率、年龄、性别、病程、AQP4血清状态或脑病灶与认知功能障碍无显著关联;黑人患者认知功能障碍较白人更明显(95%CI -2.7至-0.7)。
关键数值与推荐
- 认知功能障碍定义为MoCA<26;轻度功能障碍为MoCA 20-26/30;中度功能障碍为MoCA<20/30。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Neuromyelitis optica spectrum disorder (NMOSD) is a chronic CNS demyelinating autoimmune disorder targeting the astrocyte antigen aquaporin-4 (AQP4), typically presenting with optic neuritis, transverse myelitis, and brain syndromes. Cognitive dysfunction (CD) in NMOSD is under-recognized and poorly understood. The purpose of this study was to evaluate the prevalence and clinical variables associated with CD in NMOSD. METHODS: This observational retrospective study with longitudinal follow-up describes a clinical cohort seen in the Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. Serial Montreal Cognitive Assessments (MoCAs) were performed upon enrollment and at 6-month intervals to evaluate longitudinal cognitive function relative to demographic and disease-related factors. We used 2-tailed t test, analysis of variance, the χ2 test, linear regression for univariable and adjusted analyses and simultaneous linear regression and mixed-effects model for multivariable analyses. RESULTS: Thirty-four percent (75/219) of patients met criteria for CD (MoCA <26); 29% (64/219) showed mild dysfunction (MoCA 20-26/30), and 5% (11/219) showed moderate (MoCA <20/30) dysfunction. Patients with less neurologic disability and lower pain scores had higher MoCA scores (95% CI 0.24-0.65 and 95% CI 0.09-0.42, respectively). Patients with at least high school education scored higher on the MoCA (95% CI 2.2-5). When comparing patients dichotomized for CD, patients never on rituximab scored higher than patients only treated with rituximab (p < 0.029). There was no significant association between annualized relapse rate, age, sex, disease duration, AQP4 serostatus or brain lesions, and CD. CD was more pronounced among Black than White patients (95% CI -2.7 to -0.7). Multivariable analysis of serial MoCA did not indicate change (p = 0.715). Descriptive analysis of serial MoCA showed 30% (45/150) of patients with worsening MoCA performance had impaired language and verbal recall. DISCUSSION: To our knowledge, this is the largest study of diverse cohort to investigate CD in patients with NMOSD. Our findings demonstrate 34% of patients with NMOSD experience mild-to-moderate CD, while 30% of patients demonstrated decline on serial testing. The substantial prevalence of CD in this pilot report highlights the need for improved and validated screening tools and comprehensive measures to investigate CD in NMOSD.
引用
- Vlahovic L, McDonald J, Hinman J, et al. Prevalence, Demographic, and Clinical Factors Associated With Cognitive Dysfunction in Patients With Neuromyelitis Optica Spectrum Disorder. Neurology. 2023. PMID: 38165361. doi:10.1212/WNL.0000000000207965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。